Heidelberg, 30.01.2020. On Tuesday, BioRN kicked off this year’s Lounges with a fully booked event. Joachim Vogt, Director Search & Evaluation Western Europe at AbbVie, presented to an audience of over 60 Persons, how AbbVie is bridging science and business.
The BioRN Lounge is the prime monthly networking event for BioRN members. It is the occasion for exchange, meetings and interaction in a very relaxed atmosphere and attracting a very diverse audience.
As for several global bio-pharmaceutical companies, open innovation became also for AbbVie the key instrument to innovation. In order to deliver innovative medicines and make remarkable impact on people’s lives, partnership is essential.
Especially, AbbVie looks for external innovation partners where a long-term mutually beneficial relationships can be established.
Joachim highlighted how flexible and varied AbbVie is able to set up a partnership, using more traditional methods such as licencing and ventures, or innovative approaches like incubators.
Finally, Joachim pointed out that also the R&D pipeline in Ludwigshafen, focusing on neuroscience is the result of long-lasting partnerships and external innovation.
Our next BioRN lounge will be on February 18 as usual in the Kasselhaus by Urban Kitchen. Justin Mirus will approach the topic gene therapy and present how VectorBuilder can support scientists in pursuing their objectives. Join us at the BioRN Lounge – where science meets industry!
About BioRN
BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders.
Our vision is to develop the region into a world-leading life science cluster attracting international investments and top global talent.
BioRN has about 100 institutional members, including several top academic and research institutions, 7 pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups.